可获得性视角下韩国孤儿药供应保障体系研究及启示

杨伊凡; 谢金平; 翁婷婷; 闫丽羽; 邵蓉

doi:10.6039/j.issn.1001-0408.2023.09.01

您当前的位置：

首页 >

文章列表页 >

可获得性视角下韩国孤儿药供应保障体系研究及启示

药事管理 | 更新时间：2023-11-06

- 可获得性视角下韩国孤儿药供应保障体系研究及启示
- Research on the supply guarantee system of orphan drugs in South Korea from the perspective of accessibility and its enlightenment
- 中国药房 2023年34卷第9期页码：1025-1030
- 作者机构：
  
  中国药科大学国家药物政策与医药产业经济研究中心，南京　211198
- 作者简介：
  
  博士研究生。研究方向：医药政策与法规。E-mail：m18052039521@163.com
  教授，博士生导师，博士。研究方向：医药政策与法规。E-mail：shaorong118@163.com
- 基金信息：
  
  国家社会科学基金重大项目(15ZDB167)
- DOI：10.6039/j.issn.1001-0408.2023.09.01
  中图分类号： R95
- 纸质出版日期：2023-05-15，
  
  收稿日期：2022-11-09，
  
  修回日期：2023-03-23，
扫描看全文
杨伊凡,谢金平,翁婷婷等.可获得性视角下韩国孤儿药供应保障体系研究及启示 ^Δ[J].中国药房,2023,34(09):1025-1030.

YANG Yifan,XIE Jinping,WENG Tingting,et al.Research on the supply guarantee system of orphan drugs in South Korea from the perspective of accessibility and its enlightenment[J].ZHONGGUO YAOFANG,2023,34(09):1025-1030.
杨伊凡,谢金平,翁婷婷等.可获得性视角下韩国孤儿药供应保障体系研究及启示 ^Δ[J].中国药房,2023,34(09):1025-1030. DOI： 10.6039/j.issn.1001-0408.2023.09.01.

YANG Yifan,XIE Jinping,WENG Tingting,et al.Research on the supply guarantee system of orphan drugs in South Korea from the perspective of accessibility and its enlightenment[J].ZHONGGUO YAOFANG,2023,34(09):1025-1030. DOI： 10.6039/j.issn.1001-0408.2023.09.01.

摘要

目的

系统介绍韩国孤儿药的供应保障体系，为提高我国孤儿药可获得性提供参考。

方法

通过研究韩国孤儿药上市激励机制、储备供应机制和紧急使用机制，总结韩国孤儿药供应保障体系的基本特点和实践经验。并基于对我国孤儿药供应保障现状及现存问题的研究，提出提升我国孤儿药可获得性的具体建议。结果与

结论

韩国通过孤儿药认定渠道和配套激励政策，依托储备供应机制和紧急使用的进口途径，有效提高了孤儿药的可获得性。因此，建议我国从完善孤儿药认定和激励政策、增设孤儿药专职管理部门、优化临时进口途径3个方面，保障孤儿药的正常供应。

Abstract

OBJECTIVE

To systematically introduce the supply guarantee system of orphan drugs in South Korea， and to provide reference for improving the accessibility of orphan drugs in China.

METHODS

The basic characteristics and practical experience of supply guarantee system of orphan drugs in South Korea were summarized by studying the marketing incentive mechanism， reserve supply mechanism and emergency use mechanism. Then， based on the research on the current situation and existing problems of orphan drug supply in China， specific suggestions were put forward to improve the accessibility of orphan drugs in China.

RESULTS &

CONCLUSIONS

South Korea has effectively improved the accessibility of orphan drugs through orphan drug identification channels and supporting incentive policies， relying on the reserve supply mechanism and the import route for emergency use. Therefore， it is suggested that China should guarantee the normal supply of orphan drugs from three aspects： improving the recognition and incentive policy of orphan drugs， building a full-time management department of orphan drugs， and optimizing the temporary import path.

关键词

孤儿药罕见病可获得性供应保障韩国

Keywords

rare diseasesaccessibilitysupply guaranteeSouth Korea

references

陈敏，郎炳辰，张伶俐，等.我国进口孤儿药可及性的调查研究[J].中国药学杂志，2017，52（8）：702-705.

谷景亮，鲁艳芹，张睿，等.实现我国罕见病药物可及策略研究[J].卫生软科学，2013，27（6）：325-327.

吴佳，王高峰.孤儿药可及性问题的伦理审视[J].锦州医科大学学报（社会科学版），2020，18（2）：11-14，18.

Ministry of Food and Drug Safety.Orphan drug designation regulations（No.2018-41）[EB/OL].（2018-06-01）[2022-03-05]. https：//impfood.mfds.go.kr/CFBDD02F02?active=00035&cntntsSn=285720&cntntsMngId1=00035https://impfood.mfds.go.kr/CFBDD02F02?active=00035&cntntsSn=285720&cntntsMngId1=00035.

Ministry of Health and Welfare. Rare disease management law[EB/OL].（2020-09-12）[2022-03-22]. https：//www.law.go.kr/LSW//lsLinkProc.do?lsNm=%ED%9D%AC%EA%B7%80%EC%A7%88%ED%99%98%EA%B4%80%EB%A6%AC%EB%B2%95&chrClsCd=010202&mode=20& ancYnChk=0#https://www.law.go.kr/LSW//lsLinkProc.do?lsNm=%ED%9D%AC%EA%B7%80%EC%A7%88%ED%99%98%EA%B4%80%EB%A6%AC%EB%B2%95&chrClsCd=010202&mode=20&ancYnChk=0#.

HYEONG G L，EILEEN J S.Distribution and marketing of drugs in South Korea：overview[EB/OL].（2019-10-01）[2022-03-22].https：//uk.practicallaw.thomsonreuters.com/6-618-5565?contextData=（sc.Default）&transitionType=Default&firstPage=truehttps://uk.practicallaw.thomsonreuters.com/6-618-5565?contextData=(sc.Default)&transitionType=Default&firstPage=true.

Organisation for Economic Co-operation and Development.R&D tax incentives：Korea[EB/OL].（2020-12-15）[2022-10-22].https：//www.oecd.org/sti/rd-tax-stats-korea.pdfhttps://www.oecd.org/sti/rd-tax-stats-korea.pdf.

SON K B. Market exclusivity of the originator drugs in South Korea：a retrospective cohort study[J]. Front Public Health，2021，9：654952.

Ministry of Food and Drug Safety.2021 drug approval report[EB/OL].（2022-06-30）[2022-10-22].https：//www.mfds.go.kr/eng/brd/m_19/view.do?seq=70437https://www.mfds.go.kr/eng/brd/m_19/view.do?seq=70437.

Ministry of Food and Drug Safety.Ministry of Food and Drug Safety White Paper[EB/OL].（2021-08-20）[2022-10-22].https：//www.mfds.go.kr/docviewer/skin/doc.html?fn=20210820051540953.pdf&rs=/docviewer/result/data0013/33414/2/202203https://www.mfds.go.kr/docviewer/skin/doc.html?fn=20210820051540953.pdf&rs=/docviewer/result/data0013/33414/2/202203.

CHO I，HAN E. Drug lag and associated factors for approved drugs in Korea compared with the United States[J]. Int J Environ Res Public Health，2022，19（5）：2857.

Knowledge Ecology International.Request for Unity Korea：gleevec price reduction[EB/OL].（2009-10-10）[2022-10-22]. https：//www.keionline.org/21061#：~：text=Korean%20civil%20society%20has%20asked%20KEI%20to%20disseminatehttps://www.keionline.org/21061#:~:text=Korean%20civil%20society%20has%20asked%20KEI%20to%20disseminate，for%20trying%20to%20reduce%20the%20price%20a%2014%25.

UAEM Korea.Access to orphan drugs in South Korea ：blind spot of the Korean health system[EB/OL].（2021-06-30）[2022-10-22].https：//docslib.org/doc/2118490/access-to-orphan-drugs-in-south-korea-blind-spot-of-the-korean-health-systemhttps://docslib.org/doc/2118490/access-to-orphan-drugs-in-south-korea-blind-spot-of-the-korean-health-system.

The Korea Orphan and Essential Drug Center. Center supply drugs[EB/OL].[2022-10-22].https：//www.kodc.or.kr/drugInfo?medcinCtgryCode=Ehttps://www.kodc.or.kr/drugInfo?medcinCtgryCode=E.

赵苑旨，侯佳欣.50家医院将能用氯巴占[N].健康时报，2022-07-08（14）.

李禾.让罕见病患者有医、有药、有保障[N].科技日报，2023-01-11（8）.

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

暂无数据